Volume 4.12 | Mar 29

Mammary Cell News 4.12 March 29, 2012
Mammary Cell News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
ErbB2-Driven Breast Cancer Cell Invasion Depends on a Complex Signaling Network Activating Myeloid Zinc Finger-1-Dependent Cathepsin B Expression
This work provides a model system for ErbB2-induced breast cancer cell invasiveness, reveals a signaling network that is crucial for invasion in vitro, and defines a specific role and targets for the identified serine-threonine kinases. [Mol Cell] Abstract | Press Release

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by Impact Factor of the Journal)


Tumor Initiating but Differentiated Luminal-Like Breast Cancer Cells Are Highly Invasive in the Absence of Basal-Like Activity
Researchers demonstrate that basal-like cells are not a requirement for breast tumor aggressiveness, and that within a single tumor there are multiple “stem-like” cells with tumorigenic potential casting some doubt on the hypothesis of hierarchical or differentiative loss of tumorigenicity. [Proc Natl Acad Sci USA] Abstract

Dithiolethiones Inhibit NF-κB Activity via Covalent Modification in Human Estrogen Receptor-Negative Breast Cancer
Scientists investigated the chemical and biochemical effects of dithiolethione on NF-κB and downstream effector molecules in estrogen receptor negative breast cancer cells and murine tumor xenografts. [Cancer Res] Abstract

Growth Hormone Receptor Blockade Inhibits Growth Hormone-Induced Chemoresistance by Restoring Cytotoxic-Induced Apoptosis in Breast Cancer Cells Independently of Estrogen Receptor Expression
Researchers aim was to evaluate whether growth hormone (GH) may impact chemoresistance phenotype of estrogen receptor (ER)-negative breast cancer (BC)-derived MDA-MB-231 cell line and investigate the possible mechanisms implicated in the protective action of GH toward the cytotoxic effects of doxorubicin in both ER-positive and ER-negative BC-derived cell lines. [J Clin Endocrinol Metab]

Yin Yang 1 Plays an Essential Role in Breast Cancer and Negatively Regulates p27
Researchers suggest that Yin Yang 1 (YY1) is an oncogene and identify p27 as a new target of YY1. [Am J Pathol] Abstract

Estrogen Regulates JNK1 Genomic Localization to Control Gene Expression and Cell Growth in Breast Cancer Cells
Researchers demonstrate a functional convergence of the estrogen and c-Jun N-terminal kinase 1 (JNK1) signaling pathways at the genomic level in breast cancer cells. [Mol Endocrinol] Abstract

MiR-21 Regulates EMT Phenotype and HIF-1α Expression in Third-Sphereforming Breast Cancer Stem Cell-Like Cells
Third-sphereforming cancer stem cell (CSC)-like cells, which showed elevated CSC surface markers and sphereforming capacity as well as migration and invasion capacities, were cultured and isolated from breast cancer MCF-7 parental cells, to evaluate the role of miR-21 in regulating the CSC-like cell biological features, especially epithelial-mesenchymal transition (EMT). [Cancer Sci]

Downregulation of HuR as a New Mechanism of Doxorubicin Resistance in Breast Cancer Cells
Researchers investigated the role of HuR in the apoptosis and in the chemoresistance induced by the widely used anticancer drug doxorubicin in human breast cancer cells. [Mol Cancer] Abstract

Overexpression of Forkhead Box J2 Can Decrease the Migration of Breast Cancer Cells
Scientists demonstrate that Forkhead Box J2 can inhibit the metastasis of human breast cancer by regulating the EMT key markers E-cadherin and vimentin. [J Cell Biochem] Abstract


Limited Value and Utility of Breast MRI in Patients Undergoing Breast-Conserving Cancer Surgery
Researchers compare the accuracy of magnetic resonance imaging (MRI) and ultrasonography (US) in measuring the size of invasive breast cancer and carcinoma in situ. They also examine the utility of routinely performing MRI in addition to US before breast-conserving surgery. [Ann Surg Oncol]

The Association between Breast Cancer Prognostic Indicators and Serum 25-OH Vitamin D Levels
Scientists examine 25-OH vitamin D levels between breast cancer (BC) cases and controls and by prognostic indicators among BC cases. [Ann Surg Oncol] Abstract

Do Your Colleagues Know What They Are Missing? Share This Newsletter Now.


Adding BSGI Molecular Breast Imaging to Breast Imaging Centers Significantly Improves Breast Cancer Detection
According to the results from a new multi-center patient registry Breast-Specific Gamma Imaging (BSGI) improves breast cancer detection when added to mammography and ultrasound in the breast clinic. [Press release from Dilon Diagnostics discussing research presented at the 22nd National Consortium of Breast Centers Annual Meeting, Las Vegas] Press Release

Everolimus Plus Exemestane Improves Bone Health in Post-Menopausal Women with Advanced Breast Cancer
Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading in the bone. [Press release from EurekAlert! discussing research presented at the 8th European Breast Cancer Conference, Vienna] Press Release


FDA Clears Asuragen’s RNARetain® Pre-Analytical RNA Stabilization Device
Asuragen, Inc. announced the FDA clearance of RNARetain®, the Company’s clinically validated and cGMP manufactured sample collection and cellular RNA preservation device. Based upon patented technology, RNARetain is labeled for the collection, storage, and transportation of fresh breast tissue specimens for subsequent RNA isolation and further molecular diagnostic testing. [Asuragen, Inc.] Press Release

Breast Surgical Service Chief Monica Morrow Honored with Gianni Bonadonna Breast Cancer Award and Lecture
Monica Morrow has been named the 2012 recipient of the Gianni Bonadonna Breast Cancer Award and Lecture from the American Society of Clinical Oncology. [Memorial Sloan-Kettering Cancer Center] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 2012 Canadian Centre for Applied Research in Cancer Control (ARCC) Conference
May 28, 2012
Montreal, Canada

our events page to see a complete list of events in the mammary cell community.


Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Tenure Track Position (Johns Hopkins University)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)

Postdoctoral Position – Breast Cancer Cell Biology (Karolinska Institutet) 

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati – College of Medicine)

Postdoctoral Research Fellow (Cancer Research UK – Cambridge Research Institute) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada